Study protocol and statistical analysis plan for a randomized controlled trial evaluating the safety and feasibility of the recombinant human platelet-derived growth factor B (rhPDGF-BB)-enhanced collagen plug for complex perianal fistula healing
Background A drug-repurposing-specific phenome-wide association study (PheWAS) demonstrated that patients with a single nucleotide variant that decreases expression of platelet-derived growth factor receptor beta (PDGFR{beta}) have a higher prevalence of fistulas, suggesting that PDGFR{beta} signaling is important for tissue repair. Recombinant human platelet derived growth factor B (rhPDGF) is an FDA-approved protein-based therapeutic that signals through PDGFR{beta} to heal and regenerate cutaneous skin wounds, periodontal tissue, and orthopedic bone with a strong safety profile. We hypothesize that rhPDGF will benefit other conditions identified by PheWAS with a similar physiological mechanism as the existing indications, such as complex perianal fistulas that are ineligible for a fistulotomy. Methods and analysis This prospective, blinded, single-site study aims to enroll 12 participants, randomized at a ratio of 2:1, comparing implantation of rhPDGF-enhanced collagen to routine care procedures, and stratified by fistula etiology, idiopathic versus Crohns disease (CD)-related. The primary outcome of this study will evaluate the technical performance of the rhPDGF-enhanced collagen implant for treatment of complex perianal fistulas as measured by the proportion of participants with successful implantation of the intervention without any intervention-related serious adverse events. The secondary outcomes will assess the preliminary safety and efficacy of the intervention based on all intervention-related adverse events, total fistulas healed, rate of fistula recurrence, and change in patient-reported symptoms. Complex perianal fistulas, idiopathic or CD-related, remain a major clinical challenge in need of new multimodal treatments aimed at tissue repair and regeneration. Pharmaceutical rhPDGF stimulation of PDGFR{beta} signaling promotes healing of skin, bone, and soft tissue. PheWAS revealed fistulas as a novel indication for repurposing rhPDGF. This protocol aims to evaluate the technical performance, preliminary safety and efficacy, and feasibility of rhPDGF-enhanced collagen for healing and remission of complex perianal fistulas. Ethics and dissemination This trial was approved by the Vanderbilt University Medical Center institutional review board (IRB#240585). Results will be submitted for publication in a peer-reviewed journal.